New Study Compares Two Types of Insulin for Young People in Low-Income Countries

In many low-income and middle-income countries, traditional human insulins like isophane insulin remain the standard treatment for Type 1 diabetes, largely because they are more affordable. At the same time, newer insulin options like insulin glargine have become available and may offer benefits such as a lower risk of low blood sugar episodes. The HumAn-1 trial was designed to test whether switching to insulin glargine could make a real difference for young people managing Type 1 diabetes in settings where resources are limited.

Understanding which insulin works best in different parts of the world is important because it can help doctors and patients make informed choices based on what's actually available and what the evidence shows.

Researchers randomly assigned young people aged 7 to 25 years with Type 1 diabetes to one of two groups. One group switched to insulin glargine, a long-acting insulin given by injection (usually before bed). The other group continued their usual care, which was either isophane insulin or a premixed insulin combination, given once or twice daily as their doctor thought best.

The study included participants from three sites: one in Bangladesh and two in Tanzania. After six months, researchers used continuous glucose monitors—devices that track blood sugar levels throughout the day and night—to measure two main outcomes: how much time participants spent in a very low blood sugar range and how much time they spent in their target blood sugar range.

The primary goal was to see whether insulin glargine could reduce the risk of serious low blood sugar episodes (measured as time spent below 54 mg/dL) and improve time spent in the target range (70–180 mg/dL). These are important measures because spending too much time in either extreme—too low or too high—can affect both how people feel day-to-day and their long-term health.

By comparing a modern insulin option against the traditional option already in use, the researchers wanted to determine whether the newer approach offered real advantages for young people in low-resource settings.

This trial is one of the first to directly compare these two insulin types in low-income and middle-income countries where the choice of insulin options is often limited. The results will help guide decisions about which insulins to use and recommend in these settings, taking into account both effectiveness and practical considerations like cost and access.

For families and young people living with Type 1 diabetes in low-resource areas, studies like this one are valuable because they test treatments in the real-world contexts where they'll actually be used.

Source: The lancet. Diabetes & endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.